Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer

Core Insights - Immutep Limited is set to present the pivotal TACTI-004 Phase III trial at the IASLC 2025 World Conference on Lung Cancer, highlighting its focus on advanced non-small cell lung cancer treatment [1][2] Company Overview - Immutep is a late-stage biotechnology company specializing in immunotherapies for cancer and autoimmune diseases, particularly focusing on Lymphocyte Activation Gene-3 (LAG-3) [7] - The company aims to leverage its expertise to develop innovative treatment options and maximize shareholder value [7] Trial Details - The TACTI-004 Phase III trial evaluates the efficacy of Immutep's antigen presenting cell (APC) activator, eftilagimod alfa (efti), in combination with Merck's KEYTRUDA® and chemotherapy for first-line treatment of advanced or metastatic non-small cell lung cancer [2][4] - The trial will enroll approximately 750 patients across over 150 clinical sites in more than 25 countries, regardless of PD-L1 expression [2] Eftilagimod Alfa (efti) Profile - Efti is a first-in-class APC activator that stimulates both innate and adaptive immunity, enhancing the immune response against cancer [5] - It has a favorable safety profile and is being evaluated for various solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, and metastatic breast cancer [6] - Efti has received Fast Track designation from the FDA for first-line treatment in both head and neck squamous cell carcinoma and non-small cell lung cancer [6] Engagement with Medical Community - Immutep has received positive feedback from the lung cancer community regarding efti's safety and efficacy, indicating strong potential to change treatment paradigms for patients with advanced non-small cell lung cancer [3]